MacroGenics, Inc. (MGNX) to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th American Society of Hematology Annual Meeting
11/12/2013 12:34:24 PM
ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on targeting CD123-positive leukemic cells with its DART®-based molecule, MGD006, will be featured in an oral presentation at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans on December 7-10, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by